Moonwalk Biosciences founding team (L-R): CEO Alex Aravanis, COO Justin Valley, CBO Elaine Cheung, and president and CTO Arash Jamshidi. (Photo credit: Erin Beach)

January 4, 2024 08:00 AM EST

Cell/Gene Tx

Backed by CRISPR pioneer Feng Zhang, epigenetics biotech Moonwalk debuts with $57M

Ayisha Sharma

News Reporter

Moonwalk Biosciences has secured $57 million in seed and Series A funds to advance its epigenetics platform and preclinical pipeline in the latest endeavor by CRISPR gene editing co-pioneer Feng Zhang.

The fundraise was led by Alpha Wave Ventures with support from ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures. Moonwalk was jointly founded by Zhang and former Illumina chief technology officer Alex Aravanis, along with Arash Jamshidi and Justin Valley.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Backed by CRISPR pioneer Feng Zhang, epigenetics biotech Moonwalk debuts with $57M

Ayisha Sharma

News Reporter

Unlock this article instantly by becoming a free subscriber.

House to mark up bill targeting Chinese biotech and genomics companies

AbbVie puts $161M into new R&D site in Germany, will add 300 jobs

FDA asks for more data on Dupixent in COPD in move that could delay a decision

Epigenetic editing startup Chroma lays off staff, focusing on reaching the clinic

WuXi wants to regain client confidence amid claims of IP transfer to Chinese authorities

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Backed by CRISPR pi­o­neer Feng Zhang, epi­ge­net­ics biotech Moon­walk de­buts with $57M

Ayisha Sharma

News Reporter

Unlock this article instantly by becoming a free subscriber.

House to mark up bill tar­get­ing Chi­nese biotech and ge­nomics com­pa­nies

Ab­b­Vie puts $161M in­to new R&D site in Ger­many, will add 300 jobs

FDA asks for more da­ta on Dupix­ent in COPD in move that could de­lay a de­ci­sion

Epi­ge­net­ic edit­ing start­up Chro­ma lays off staff, fo­cus­ing on reach­ing the clin­ic

WuXi wants to re­gain client con­fi­dence amid claims of IP trans­fer to Chi­nese au­thor­i­ties

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

Backed by CRISPR pioneer Feng Zhang, epigenetics biotech Moonwalk debuts with $57M

House to mark up bill targeting Chinese biotech and genomics companies

AbbVie puts $161M into new R&D site in Germany, will add 300 jobs

FDA asks for more data on Dupixent in COPD in move that could delay a decision

Epigenetic editing startup Chroma lays off staff, focusing on reaching the clinic

WuXi wants to regain client confidence amid claims of IP transfer to Chinese authorities

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations